Podcasts about j j

(1) "Respect Burgers" from Jason for Ja 3 shoes, DJ Okoth & Mem Women's Soccer (2) Jonah Dylan, Comm Appeal Tigers FB, on WR Brahm and Tiger FB expectations (3) Jonah Dylan, Comm Appeal Tigers FB, on WR Brahm and Tiger FB expectations and salutations for the day from J&J

Memphis Football--Jonah Dylan, Memphis Commercial Appeal, with J&J on the Tigers new receiver Braham Jr. and expectations

Tom E. Curran and Phil Perry break down the Patriots first day of joint practices with the Vikings. Phil offers his overall impressions, as he was in Minnesota to witness the whole thing. He then breaks down the offense and defense, and he explains what he saw from Drake Maye. Finally, the guys hit on Stefon Diggs' arc and what Patriots fans can expect from him.0:33 - Phil Perry breaks down what he saw from the Patriots offense in joint practice against the Vikings3:06 - Drake Maye's numbers from practice5:23 - Phil Perry breaks down the Patriots defense7:11 - Mike Vrabel and Drake Maye speak more about Maye's leadership15:13 - How has Mike Vrabel as the Patriots are now a few weeks into training camp?20:52 - How did everyone else look?23:11 - What kind of trajectory is Stefon Diggs on? WATCH every episode of the Patriots Talk podcast on YouTubeFollow NBC Sports Boston:NBCSportsBoston.comX @NBCSpatriotsFacebookInstagramTikTok

This week  J  & J dig into Jared's hilarious origin story as a summer camper in New England, and how it still resonates with his life today. The episode kicks off with listener feedback on Jared's ongoing Summer Dating Challenge, followed by a laugh-out-loud “Icky or Picky” that's both “yummy” and divisive. Next, the hosts answer a listener's question about how to date more intentionally in a world full of people still "figuring out their relationship type." Finally, J+J wrap up with a Red Flag or Deal Breakers, where they dive into travel compatibility, the chronic relationship type, and a bold move from someone handing out their number. 00:00 - Intro 13:00 - Jared's New England Camp Days 20:39 - Summer Dating Challenge 39:12 - More Is Not More 54:01 - Different Vacation Styles in Couples #Dating #Advice #Hinge #Debate #RedFlag #Dealbreaker #DatingApps #Podcast #Summer Learn more about your ad choices. Visit megaphone.fm/adchoices

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Diana: Relentless passion.Breast cancer treatment is long overdue for a revolution. Diana Tucker, CEO of SenoGuard, is leading the charge with an innovative alternative to post-lumpectomy radiation. Using advanced cryoablation technology, SenoGuard freezes the cavity where a tumor is removed, eliminating residual cancer cells in one procedure.Radiation has been the standard of care for decades, but it comes with significant physical, emotional, and financial costs. Diana explained in today's episode, “Radiation is horrible both clinically and cosmetically. It changes the shape, size, and feel of the breast. Many women face long-term emotional and physical side effects.” She shared the tragic story of a young breast cancer survivor whose radiation treatment ultimately damaged her heart. “I am very passionate about eliminating radiation if at all possible,” she said.SenoGuard's approach simplifies treatment. “The patient goes in for her tumor excision, and immediately we freeze the cavity where the tumor has been removed,” Diana said. “It's one and done. The patient can go back to work the very next day.” This innovation not only reduces the physical toll on patients but also addresses significant disparities in access to care. Many women forego lumpectomies because daily radiation sessions are unaffordable or inaccessible, especially in rural areas. Diana noted, “Almost 30% of women who qualify for a lumpectomy choose mastectomy instead because they can't afford the time or cost of radiation.”To bring this groundbreaking technology to market, SenoGuard is raising capital through a regulated investment crowdfunding campaign on WeFunder. Diana emphasized the importance of public support, saying, “Everybody knows someone who has had breast cancer. By investing, people feel they are not just supporting a cause but making a difference for society.”SenoGuard's cryoablation technology has the potential to transform breast cancer treatment, making it less toxic, more accessible, and kinder to patients. By supporting their crowdfunding campaign, you could help bring this life-changing innovation to millions of women.tl;dr:Diana Tucker shared how SenoGuard's cryoablation technology eliminates the need for post-lumpectomy radiation.Radiation's side effects often force women to choose mastectomies, highlighting the need for better options.SenoGuard's innovation reduces treatment time, costs, and disparities in accessing breast cancer care.Diana described her relentless passion and how it drives her to overcome challenges in her work.SenoGuard is raising funds via a WeFunder campaign to bring this life-changing technology to market.How to Develop Relentless Passion As a SuperpowerDiana Tucker's superpower is her relentless passion for solving problems she truly believes in. As she explained in today's episode, “When I have a sincere understanding, I become very passionate, enthusiastic, and relentless to get that…across the finish line.” Her superpower drives her to tackle challenges with unwavering determination, especially when the stakes are high.Story Illustrating SuperpowerDiana shared a story from her early career, where she was tasked with bringing a French ophthalmology solution to the U.S. market. “The CEO told me, ‘If you can figure out how to bring this over to America, you have a job. If you can't, you're fired.'” Fueled by determination, she successfully introduced the technology, which became the standard of care. Years later, an ophthalmologist recognized her contribution with heartfelt gratitude, highlighting the profound and lasting impact of her work.Tips for Developing the SuperpowerFind Your Passion: Identify problems that deeply resonate with you to fuel your enthusiasm and drive.Share Your Vision: Build a team by inspiring others with your passion and clear vision.Never Give Up: When faced with roadblocks, find creative workarounds to keep moving forward.Believe in Yourself: Confidence in your abilities is key to overcoming challenges and achieving your goals.By following Diana's example and advice, you can make relentless passion a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDiana Tucker (she/her):CEO, SenoGuardAbout SenoGuard: SenoGuard is pioneering a transformative approach to breast cancer treatment by offering a radiation-free alternative following lumpectomy. Our innovative technology uses advanced cryoablation--freezing residual cancer cells during surgery--to eliminate the need for weeks of post-op radiation.This method significantly reduces patient burden, especially for the 28% who face barriers like distance, cost, or time constraints.Supported by National Science Foundation grants, SenoGuard's solution is designed to be accessible in community hospitals, expanding treatment options globally. Led by a seasoned team with over a century of combined experience in women's healthcare, SenoGuard is committed to enhancing patient outcomes and accessibility.Website: SenoGuard.comCompany Facebook Page: facebook.com/senoguardOther URL: wefunder.com/senoguardincBiographical Information: Diana Tucker is a strategic marketing executive with a distinguished track record in launching and growing innovative, paradigm-shifting medical technologies. With deep expertise in market analysis and opportunity identification, she has led high-impact global marketing initiatives across diagnostics, medical devices, and oncology. Known for her ability to anticipate market trends and apply creative strategies that drive adoption of innovative products, Diana has held leadership roles at companies such as Agendia, AMO, and J&J; as well as being a contributing editor for Thompson Reuters Biomedical Business International newsletter covering financial impacts of emerging technologies across all surgical specialties worldwide.  Diana has continually demonstrated her talent for turning unmet clinical needs into successful business opportunities. Diana holds a B.S. in Molecular & Cellular Biology from UC Irvine and an MBA in Marketing from Pepperdine University.Personal Facebook Profile: facebook.com/dianatuckerLinkedin: linkedin.com/in/dianaltuckerSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Rancho Affordable Housing (Proactive), and Dopple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear |  Matthew Mead, Hempitecture |  Michael Pratt, Qnetic | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on August 19, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, August 20, 2025, at 12:00 PM Eastern. Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on "Your Portal, Your Future: How to Choose the Right Reg CF Platform." With so many investment crowdfunding portals available today, selecting the right one can be overwhelming for both founders and investors. In this session, Devin will break down the critical factors to consider—such as platform fees, audience demographics, compliance support, industry focus, and overall user experience. Whether you're a founder planning a raise or an investor exploring where to put your dollars to work, you'll walk away with a clearer understanding of how to evaluate and choose the platform that best aligns with your goals. Don't miss this practical, insight-packed hour designed to help you take your next step in the Reg CF ecosystem with confidence.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Apply for the Live Pitch here. VIPs get access to our better-than-in-person networking, including backstage passes, VIP networking and an exclusive VIP webinar! Get your VIP access for just $25. A select group of affordable sponsorship opportunities is still available. Learn more here.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern.Future Forward Summit: San Francisco, Wednesday, June 25 · 3:30 - 8:30 pm PDT.Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Impact Accelerator Summit is a live in-person event taking place in Austin, Texas, from October 23–25, 2025. This exclusive gathering brings together 100 heart-centered, conscious entrepreneurs generating $1M+ in revenue with 20–30 family offices and venture funds actively seeking to invest in world-changing businesses. Referred by Michael Dash, participants can expect an inspiring, high-impact experience focused on capital connection, growth, and global impact.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

This Day in Legal History: Medicare and Medicaid Signed into BeingOn July 30, 1965, President Lyndon B. Johnson signed the Social Security Amendments of 1965 into law, creating the Medicare and Medicaid programs. The signing took place at the Truman Library in Independence, Missouri, with former President Harry S. Truman—an early advocate for national health insurance—present and symbolically receiving the first Medicare card. Medicare was designed to provide hospital and medical insurance to Americans aged 65 and older, regardless of income or medical history. Medicaid, created alongside Medicare, offered healthcare assistance to low-income individuals and families.At the time, nearly half of Americans over 65 had no health insurance. The passage of Medicare was a landmark achievement of Johnson's Great Society initiative and built on decades of political struggle over healthcare reform. The legislation amended Title XVIII of the Social Security Act and was strongly opposed by many in the medical establishment and conservative politicians who labeled it as “socialized medicine.” Nevertheless, the program gained rapid popularity and provided immediate relief to millions.Administered by the federal government, Medicare initially had two parts: Part A, covering hospital insurance, and Part B, covering outpatient and physician services. It has since evolved to include prescription drug coverage (Part D) and options for private plans (Medicare Advantage). The law reshaped the American healthcare landscape and established the principle that access to healthcare for seniors was a federal responsibility.The U.S. Senate confirmed Emil Bove, a former lawyer for Donald Trump and senior Justice Department official, to a lifetime seat on the 3rd U.S. Circuit Court of Appeals in a narrow 50-49 vote. Bove faced unified Democratic opposition and criticism from over 900 former DOJ employees, who claimed he undermined the department's integrity. His nomination prompted a Democratic walkout during the Senate Judiciary Committee's vote and drew sharp condemnation from Senate Majority Leader Chuck Schumer.Despite controversy, Republicans praised Bove's background as a federal terrorism prosecutor and his legal work defending Trump in several criminal cases. His confirmation shifts the appellate court's balance back in favor of Republican appointees. Critics cited Bove's alleged directives that defied judicial authority and political interference in a corruption case against New York Mayor Eric Adams. Bove denied wrongdoing in both instances. His confirmation is part of Trump's renewed effort in his second term to reshape the judiciary, following over 230 appointments in his first term. Trump has also nominated another close adviser, Jennifer Mascott, to the same court.Trump lawyer Bove confirmed to US appeals court, overcoming Democratic opposition | ReutersBove Confirmed to Appeals Court After Whistleblowers Emerge (1)A White House crypto task force established by President Trump is set to release a highly anticipated report outlining the administration's policy goals for the digital asset sector. The report, expected Wednesday, will address tokenization, market structure legislation, and a regulatory framework for blockchain-based financial products. Created by executive order shortly after Trump took office in January, the group is led by Bo Hines and includes top officials such as Treasury Secretary Scott Bessent and SEC Chair Paul Atkins.The document is expected to support expanded use of tokenization, which converts traditional assets like stocks and real estate into blockchain-based tokens. The report may call on the SEC to create a framework enabling firms like Coinbase to offer tokenized securities, though specific language remains under wraps. It will also outline the White House's preferences for crypto legislation currently advancing in Congress, including follow-up to the recently passed stablecoin law.Trump has made pro-crypto policies a centerpiece of his administration, reversing many of the enforcement actions taken under President Biden, such as lawsuits against Coinbase and Binance. While the industry sees the report as a roadmap for mainstream integration, concerns remain about conflicts of interest, particularly given Trump's financial ties to crypto ventures and meme coins. The administration has denied any ethical violations.White House set to unveil closely watched crypto policy report | ReutersThe Trump administration has formally requested the release of grand jury transcripts related to Jeffrey Epstein and Ghislaine Maxwell, citing public interest and mounting pressure over the government's handling of the sex trafficking cases. Prosecutors filed late-night motions with U.S. District Judges Richard Berman and Paul Engelmayer, arguing that the sealed testimony should now be disclosed, though the judges had previously asked for stronger legal justification. Grand jury records are typically secret, with limited exceptions for disclosure.Trump said he directed Attorney General Pam Bondi to seek the unsealing after the Justice Department reaffirmed its conclusion that Epstein died by suicide and that there was no list of elite clients—a stance that frustrated some Trump supporters who suspect a cover-up. Epstein died in 2019 before his trial; Maxwell, convicted in 2021, is serving a 20-year sentence and has appealed to the Supreme Court to overturn her conviction.In a related effort, a Florida judge recently denied a separate request to release grand jury records from earlier state investigations into Epstein, ruling they did not meet legal exceptions. Even if the federal judges allow the current transcripts to be unsealed, the documents may not reveal new information, since much of the testimony was covered during Maxwell's trial. The transcripts also wouldn't encompass the full scope of investigative material held by the government.Deputy Attorney General Todd Blanche, a former Trump lawyer, recently met with Maxwell for two days, reportedly seeking any names or evidence she could provide about others potentially involved. Neither Blanche nor Maxwell's attorney has commented in detail on those meetings.Trump administration asks judges to release Epstein, Maxwell grand jury transcripts | ReutersA Massachusetts jury has ordered Johnson & Johnson to pay over $42 million to Paul Lovell, who developed mesothelioma after decades of using the company's talc products. Lovell and his wife sued in 2021, claiming the talc contained asbestos that he unknowingly inhaled, and accused J&J of failing to warn consumers despite knowing the risks. The jury awarded damages for pain, suffering, and medical costs.J&J denied any wrongdoing, calling the verdict “junk science” and saying its products are asbestos-free and safe, with plans to appeal the decision. The company ended U.S. sales of talc-based baby powder in 2020. This case adds to a string of multi-million-dollar verdicts against J&J in talc-related mesothelioma lawsuits, although some have been overturned on appeal.J&J is facing over 63,000 active lawsuits, and possibly up to 100,000 claims in total, most alleging ovarian cancer from talc use. The company's attempts to resolve the claims through bankruptcy have failed in court three times, including a $10 billion settlement proposal rejected in March. The Lovell case is part of ongoing litigation that continues to test J&J's legal strategy and product safety claims.Johnson & Johnson ordered to pay $42M after jury finds talc caused man's cancer | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

(1) Caitlyn Clark update, Taylor Rooks gets married & J&J on HS earrings & more (2) Frank Bonner, Daily Memphian Tigers Football, on Memphis QB & Silverfield

Hear Christopher McKim's journey with moderate to severe plaque psoriasis and the latest clinical trial results from dermatologist, Dr. Christine Cornejo. Join this discussion with moderator Archie Franklin as Christopher McKim, a BMS employee living with moderate to severe plaque psoriasis, and Dr. Christine Cornejo, Director and US Medical Engagement Lead for Dermatology and Rheumatology at BMS, offer a patient and physician's perspective on treating plaque psoriasis from the inside. Listen as Chris presents his journey along with Dr. Cornejo addressing effectiveness and safety information with clinical trial results for a prescription oral treatment option. The intent of this episode is to encourage those who have moderate to severe plaque psoriasis to work with their health care provider to find a treatment option that is right for them. This episode is sponsored by Bristol Myers Squibb. For more information view Full Prescribing Information and Medication Guide . ·       (0:00)   Intro to Psoriasis Uncovered and guest welcome to Bristol Myers Squibb employee and patient Christopher McKim and Dr. Christine Cornejo, Director and US Medical Engagement Lead for Dermatology and Rheumatology at Bristol Myers Squibb. ·       (2:15)  Where the journey to finding the right treatment option for Chris and his moderate to severe plaque psoriasis began.  ·       (3:09)   The decision by Chris and his provider to try an oral systemic medication. ·       (3:28)  The effects and impact of an oral systemic treatment for Chris and his plaque psoriasis. ·       (4:09)   Dr. Cornejo addresses efficacy and clinical trials results. ·       (5:58)   Common side effects and safety concerns for the treatment Chris and his health care provider decided to try.   ·       (6:28)   Health considerations patients and providers should discuss prior to using a systemic treatment.    ·       (6:54)   What to do should side effects occur. ·       (7:10)   How Chris feels with clearer skin after making a change in treatment. ·       (8:14)   Indication and Important Safety Information. Key Takeaways: ·       Moderate to severe plaque psoriasis is a systemic disease.    ·       If you're ready to treat from the inside there is a treatment option that may help.   ·       Work with a health care provider to find the right treatment for moderate to severe plaque psoriasis.   ·       Be proactive by taking steps to learn about treatment options including effectiveness, side effects, safety concerns, and what should be discussed with a health care provider before beginning a new treatment for plaque psoriasis.  Guest Bios:   Christopher (Chris) McKim joined BMS in June of 2022. In his current role he is a Regional Marketer for the dermatology division, prior to that he provided support for 9 Therapeutic Area Specialists for the Pacific South District in the GI division.  Prior to joining BMS, Chris worked at Sanofi, J&J, Leo Pharma, and Sun Pharma in various field and home office roles. Chris resides in beautiful San Diego with his family Susan (wife), Morgan 18, Maddy 16, Mason 14 and two Golden Retrievers and enjoys traveling, cooking and anything associated with the ocean (Deep Sea Fishing, S.C.U.B.A. diving, snorkeling, and boogie boarding). Dr. Christine Cornejo joined Bristol Myers Squibb in 2024 as Director, Medical Engagement Lead for Dermatology and Rheumatology. Prior to joining BMS, she practiced dermatology at Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA, where she specialized in melanoma and high-risk skin cancer management and served as the Director of Confocal Microscopy. She also served as an Instructor at Harvard Medical School and led the Immunology and Infectious Diseases course for 1st year medical students. Resources: Current Oral Systemic Treatments For additional questions about treatment options contact the NPF Patient Navigation Center

(1) Hulk Hogan passed away, OVER/UNDERS on Memphis FB, Memphis Hoops (2) Drew Hill, Daily Memphian, with J&J on Grizz summer and the stadium lease

(1) "Cap or No Cap" Silverfield #16th best coach? Grizzlies Lease go or no go? (2) Jessica Benson, Grind City, w/J&J on Memphis, the Big 12, & Grizz Summer

(1) ..."Cam" Mr. Beast winner continued then news of Ozzy Osbourne passing away at 76 (2) Justin Fuente joined J&J to discuss Memphis, stepping into radio, and NIL (3) NFL notes including 49ers news, Raiders, and Pete Carroll

DARKNIGHT | SESSION LIVE Welcome to the real world ! Produit par JÜJÜ sur MAX FM 94.5 (Entre 2004 et 2005). DARKNIGHT est maintenant en podcast tous les lundis, sur darknight.fr. Programmée sur Max FM de septembre 2004 à juillet 2005, DARKNIGHT était une émission fait référence à la tentative d'un genre de se transmettre dans un nouveau domaine intellectuel de curiosité musicale. Qui partait du principe que les musiques électroniques ne sont pas uniquement destinées à être diffusées le week-end ! Diffusée sur la région de Grenoble. (avec plus de 500 000 auditeurs potentiels), DARKNIGHT te proposait un programme varié hors du commun.

(1) William Bedford, Memphis Tigers, Bedford, Derrick Rose with Gary Parrish archive (2) Bennett Doyle joins J&J in-studio and talks about Family Vacas (3) Bennett Doyle with J&J on the Titans (4) CEO and the mistress

J&J high school jobs, Summer Grizz & Iisalo Dandridge NCAA & Lionel Hollins fun

The show opens with June's PPI numbers and we were below expectations, showing inflation still isn't a problem, despite the dire warnings from so many. VP Vance cast the tie breaking vote to push the first recission bill through, cutting $9B in spending, including $1B for NPR and PBS. President Trump also announced saving the largest natural gas energy plant in all of North America while he was in Pennsylvania. Then, today, he announced a huge deal with the country of Bahrain. We have to return to more Epstein conversation, but this time, I think I finally have a much better handle on the strategy of this White House. We use a piece produced by CNN's Kaitlin Collins to illustrate what I believe is happening behind the scenes. Next, we dive into an undercover piece from the O'Keefe Media Group catching a J&J scientist throwing their Covid-19 vaccine under the bus. Other scandals discussed include Sen. Adam Schiff's (D-CA) attempt to re-frame his mortgage fraud woes and Sen. Rand Paul (R-KY) wants criminal charges brought on Dr. Anthony Fauci. The Trump administration is halting all access of illegals to Federal programs, meant to save up to $40B annually. An anti-Semitic professor at Georgetown has been removed as Islamic studies department chair. Trump has convinced a dozen Republicans to support stopping any attempt to form a CBDC. We close with another trade deal win for the United States with Indonesia. And, finally, one of Trump's judge appoints gets through the Senate; it only took six months. Please take a moment to rate and review the show and then share the episode on social media. You can find me on Facebook, X, Instagram, GETTR,  TRUTH Social and YouTube by searching for The Alan Sanders Show. And, consider becoming a sponsor of the show by visiting my Patreon page!!

(1) Memphis needs to win football games... and more in J&J's "Cap or No Cap" (2) Jonah Dylan, Memphis Commercial Appeal, on Tigers & who will be starting QB

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies. 00:00 Introduction and Guest Background00:56 Founding Thebans and Career Highlights01:43 Leadership at Merck and J&J02:18 Innovative Approaches at Parabilis Medicines04:09 Defining and Tackling Undruggable Targets09:27 Multivalent Drug Design and Bispecifics13:53 AI and Data Science in Drug Development19:28 Building and Leading World-Class Teams25:41 The Importance of Holding Conviction as an Entrepreneur26:25 Learning from Setbacks in the Biotech Industry30:10 Challenges and Innovations in Drug Development32:28 Navigating the Ups and Downs of the Biotech Industry36:02 The Mission and Future of Parabilis40:35 Personal Reflections and Advice for Entrepreneurs46:46 Book Recommendations and Closing Thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Mathai Mammen;LinkedIn: https://www.linkedin.com/in/mathai-mammen/Website: https://parabilismed.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

(1) John's trip, Summer League moves, Mashack, GG Jackson and roster Grizz look (2) J&J go to Jessica Benson in Salt Lake City Summer League on Cam Spencer etc

(1) Odds to be Rookie of the Year for Coward and Grizz process hiring Tuomas Iisalo (2) Bennett Doyle from Grind City Media joins J&J in-studio (3) Round 2 of the NBA Draft live tonight on 92.9 FM ESPN

(1) Cedric Coward picked at #11 by the Memphis Grizzlies & J&J like the pick (2) Drew Hill from the Daily Memphian with J&J on Coward pick & Grizz plan Ja/J

(1) Brad Stevens & Celtics wizardry & J&J remember Joe Lee McNelis remembered (2) Grizzlies #16 pick and a mock draft look for tonight's 1st round

(1) Oklahoma City win the 2025 NBA Title and got some injury help with Haliburton (2) J&J on Durant trade and what the Grizzlies should do with #16 1st Rounder

Day 2: J&J on Stephen A. Smith Memphis crime follow up comments

Jason Fitz--with J&J on Stephen A. Smith using crime stats to hammer Memphis and referencing Jimmy Butler

(1) OKC wins Game 5 & Stephen A Smith blames Memphis crime for player issues (2) Jessica Benson joins J&J on Bane trade + Ja Morants tweets love for the 901

Science and technology will bring more change to health care over the next decade than we saw in the past century, says Joaquin Duato, Chairman and CEO, Johnson & Johnson, and a 2025 Distinguished Leadership Award honoree. What drives his confidence, and how is the company creating this future?     Join David K. Young and Duato to discover what he has learned in 36 years at J&J, how the company innovates in science and technology, and how the company supports employees and communities.  This Leadership in Challenging Times discussion is featured as a C-Suite Perspectives podcast and a special CED Policy Watch Webcast. Leadership in Challenging Times features timely and insightful discussions with the outstanding CEOs who are recipients of CED's Distinguished Leadership Awards. Business leader honorees discuss the unprecedented challenges facing the nation and how they are helping chart a path forward for both their companies and communities in which they operate.      (04:08) Leadership Philosophy and Company Culture (06:48) Secrets to Johnson & Johnson's Longevity (09:11) Transforming Health Care with Science and Technology (12:09) Investment Strategies in Health Care Innovation (15:53) Advancing Technology and AI at Johnson & Johnson (18:38) Addressing the Global Health Care Workforce Shortfall (19:41) Ensuring Access to Health Care for Underserved Communities   For more from The Conference Board:  CED Announces Recipients of Its 2025 Distinguished Leadership Awards  CED Distinguished Leadership Awards Celebration 

(1) Ja Morant leaves Mike Miller agency and more on Game 4 of the NBA Finals (2) Anthony Sain from BCM joins J&J to discuss Ja agent move and more

NFL and local football: Olive Branch, Miss State and NFL Super Bowl Champion KJ Wright in-studio with J&J

(1) ... Okc vs Pacers continued...then Calvin Austin is in prime position to be the #2 receiver for Aaron&Steelers (2) Jason Fitz, Yahoo! Radio, joins J&J and reviews NBA Finals & a look at NFL

Memphis Tigers: Frank Bonner, Daily Memphian, with J&J on Silverfield expectations and Memphis' QB situation

(1) Zach Edey is out for the start of '25 season. J&J toss out some options (2) Game 2 NBA Finals SGA cooked and continues to cook + Beasley 1-v-1 v Lance Stephenson

(1) Respect Burgers for Michael Beasley, Sons of famous dads, & John's Riley (2) Geoff Calkins on Grizz decisions in light of Edey injury and OKC vs. Pacers (3) J&J presented by Robert Irwin Jewelers & more on Rick Carlisle & Pacers

(1) Rundown on Memphis adding Utah State to basketball schedule, NBA Finals and Aaron Rodgers (2) Legends talk from J&J on Novak Djokic, Agassi and Tennis (3) "Fade Brad" start/ NBA

..."Fade Brad" NBA continued from Hour 2 (1) NBA finals history (2) Parth Upadhyaya from the Daily Memphian on the Tigers non-conf and more (3) Sonic sponsors J&J + more on Novak Djokic

2025晨鐘課－每天，都是新的起點 以歷史智慧滋養生活，點亮2025每一天！ 借鑑過去，活在當下，展望未來！ 粵語廣播網站 (時兆出版社授權錄製) https://soundcloud.com/mediahk Podcast@靈修廣播站 6月7日 無法測度的愛 「上帝愛世人，甚至將他的獨生子賜給他們，叫一切信他的，不致滅亡，反得永生。」 約翰福音 3：16   你有最喜歡的《聖經》經文嗎？如果有的話，它對你來說意味著什麼？〈約翰福音〉第3章16節是《聖經》中最被廣泛引用的經文之一。蘇格蘭教會的牧師威廉．巴克利（William Barclay）稱其為「福音的精華」，也有人稱它為「迷你《聖經》」。 1885年6月7日晚上，在倫敦大都會禮拜堂，查理斯．司布真（Charles H. Spurgeon）以〈約翰福音〉第3章16節為主題進行了一場感動人心的佈道。他說：「這個世界有什麼值得上帝去愛的呢？荒漠中長不出芬芳的花兒。對祂的敵意，對祂真理的憎惡，對祂律法的漠視，對祂誡命的反叛；這些都是覆蓋荒原的荊棘和蒺藜；就是沒有任何可愛的東西在這裡盛放。」但是，「在人類的廢墟中，耶和華展示出祂對人類的深愛……當至高的上帝賜下祂的兒子時，祂其實是賜下了祂自己，因為耶穌在祂永恆的本性中並不比上帝遜色。當天父將聖子賜給我們時，就是將自己給了我們。祂還保留了什麼不給我們嗎？祂把自己的一切都賜下了：就是祂自己。誰能衡量這份愛呢？」 J．愛德溫．哈蒂爾（J. Edwin Hartill）從〈約翰福音〉第3章16節中延伸出十二個「最」字： 1「上帝」：最無與倫比的愛人；2「愛」：最深切的程度；3「世人」：最廣大的受眾；4「甚至將……賜給」：最無私的行為；5「他的獨生子」：最美好的禮物；6「叫一切」：最唾手可得的機會；7「信」：最簡單的要求；8「他」：最無法抗拒的吸引；9「不致滅亡」：最偉大的應許； 「反」：最明顯的反差；回「得」：最無可置疑的確定；以及回「永生」：最豐厚的財富。 短短的一句話中，包含了多少令人讚歎的深意啊！如果你用自己的名字來替換以上章節中的「世人」和「一切信他的」，讀起來就會有更切實的意義。因為，上帝也深愛著你！ #媒體佈道部 #港澳區會 #聲音書 #時兆出版社 #每天，都是新的起點 #本書由時兆出版社授權刊載

(1) Over/Unders - SGA points, total series games for NBA Finals, Crazy NY sports radio rants (2) Drew Hill, Daily Memphian Grizzlies Beat, joins J&J to discuss Grizz moves, the Finals, NY Knicks coaching search and parenthood

(1) J&J discuss if Memphis is the biggest loser in college basketball off-season (2) John Henson, Former NBA Star/North Carolina and Field of 68, discussed UNC NIL, Kentucky and college hoops with J&J

(1) Memphis Football times released (2) Story about All-American Rejects & "Fade Brad" pick for tonight (3) Rob Dauster-College BB Insider Field of 68-on Tourney expansion & Haggerty (4) J&J on Aaron Rodgers, Steelers OTAs, & Pickens with Pittsburgh

(1) J&J's Over Unders on years remaining for Conley in the NBA & NYK v Pacers (2) Drew Hill, Daily Memphian, on Mike Conley, Grizz vs. Thunder future & CBB

(1) J&J the improbable comeback by the Indiana Pacers and Haliburton (2) Drew Hill joins J&J on Jaren contract, SGA, NBA Playoffs & more on Precious

(1) "Fade Brad" with special info on the Cosby Family and Knicks game tonight (2) Coach Norton Hurd IV - joins J&J to discuss amazing Memphis EYBL NIKE event

(1) J&J discuss the Pacers, Knicks and the Oklahoma City Thunder moving on past Jokic and the Nuggets (2) Jason gives a full report on Massive NIKE EYBL event in Memphis & Ja shoes

Josh Pastner, UNLV Head Coach, joins J&J (5/14) to discuss Memphis vs. UNLV matchup, recruiting, and Tigers

A wild Reddit thread sparks a debate about boundaries and bizarre birthday gestures. When a woman discovers her friend tattooed her full first, middle, and last name on her wrist to "celebrate her birthday," Jeff and Jeremy unpack the awkwardness, red flags, and whether they'd stay friends with someone who pulled that stunt. The conversation takes a heartfelt turn as they explore the emotional weight of "in memoriam" car stickers, questioning their purpose and impact. With callers like Lindsay, a grief advocate, and a father honoring his late daughter, J+J gain new perspectives on grief, memory, and personal expression. From tattoos to car decals, this episode is a rollercoaster of humor, empathy, and real talk. #AITA #GriefTalk #TattooDrama Length: ~45 minutes Topics: Reddit AITA, tattoos, grief, car stickers, personal boundaries Call-in Guests: Lindsay (Grief Advocate), Anonymous Father Hashtags: #JeffAndJeremy #RedditAITA #GriefAndMemory #TattooDebate

Jayson Tatum injury--Jessica Benson, Grind City Media/Grizzlies Radio Host, joins J&J to discuss potential Tatum injury and the NBA

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

(1) J&J talk about NIL and Memphis' pursuit of PJ Haggerty return (2) Anthony Sain, Bluff City Media Host, joins J&J on Grizz coach move & NBA

The federal drug purchasing program known as 340B was created in 1992 to help select provider organizations stretch scarce resources to care for patients. More than three decades later, health systems of all shapes and sizes have come to rely on 340B for their financial sustainability. But the program has come under criticism. And in recent years, it's been under more scrutiny, with manufacturers, state governments, and federal regulators proposing changes to how it operates. In this episode, host Abby Burns invites Advisory Board experts Gina Lohr and Chloe Bakst to unpack the origin and controversy around 340B. They debate whether 340B has strayed from its intended purpose and break down the proposed changes to the program, how likely they are to go into effect, and what those changes would mean for health systems. Plus, stay tuned to the end of the episode, where co-host Rae Woods discusses the recent healthcare-focused executive order and what it signals for the future of this administration's drug policy. Let us know what you think about today's discussion, or share your ideas for future episode topics by leaving us a voice message or emailing us. Links: 340B Drug Pricing Program 340B reimbursement cuts may be looming: What you need to know J&J's 340B rebate model is receiving pushback. Here's why. Congress is weighing spending cuts. How will they impact healthcare? [Relentless Health Value] EP448 (Part 1): 340B: Where It Started, Where It Is Now, and Who Is Really Benefiting From This Massive Program, With Shawn Gremminger [Relentless Health Value] EP448 (Part 2): 340B: Why Employers Should Probably Care About What's Happening Here, With Shawn Gremminger GLP-1 innovation showcase A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

(1) Ja tweets another dramatic quote "be careful what you wish for" (2) Jessica Benson, Grizzlies Radio & Grind City Media, w/J&J on Grizz & more

(1) Jeanty/NFL Draft contin' then "Fade Brad" 3 picks for tonight's NBA Games including NYK, OKC/Griz & Clips (2) Adam Chernoff, Right Angle Sports, with J&J on 2025 NFL Draft & Shannon Sharpe stepping away from ESPN & J&J salute to Will Barton